The article discusses emerging research suggesting that GLP-1 medications, commonly prescribed for obesity and diabetes (including brand names Ozempic, Mounjaro, Wegovy, and Zepbound), may also have potential in treating addiction. With approximately 15% of Americans having tried a GLP-1 medication, researchers are exploring its broader impacts beyond diet and metabolic health. Dr. Eugene Lucas notes that physicians have observed patients with concurrent addictive disorders, particularly alcohol use disorder, experiencing reduced alcohol consumption or cessation while on GLP-1 medications.

Two studies support these observations: a large Swedish study of over 200,000 individuals linked GLP-1 drug use with a decreased risk of hospitalization due to alcohol use disorder, while a Washington University School of Medicine study of 600,000 veterans with type 2 diabetes found an association between GLP-1 medications and a lower risk of developing any substance use disorder. Dr. Ziyad Al-Aly highlights the novelty of a medication potentially effective across multiple addictions, suggesting that GLP-1s might target the brain’s craving center, thereby diminishing addictive urges. However, the article emphasizes that while these findings are promising, treating addiction with GLP-1 medications is not yet FDA-approved, and further research is necessary to substantiate these effects and understand the underlying mechanisms. Read the full article here.

This is a summary. Read the original at health.yahoo.com.